5月7日，佰仁医疗今日收盘112.35元，上涨1.33%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到90.53倍，总市值154.36亿元。 北京佰仁医疗科技股份有限公司是国内技术领先的、专注于动物源性植介入医疗器械研发与生产的高新 技术企业,主要产品主要包括心脏瓣膜置换与修复、先天性心脏病植介入治疗、外科软组织修复等。 最新一期业绩显示，2025年一季报，公司实现营业收入1.00亿元，同比31.30%；净利润3250.43万元， 同比290.69%，销售毛利率85.72%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)104佰仁医疗90.53105.4911.99154.36亿行业平均 49.0247.364.56104.18亿行业中值36.2537.322.4146.91亿1天益医疗-1703.20-2917.401.8221.70亿2澳华内 镜-638.65320.325.1267.31亿3诺唯赞-417.24-493.492.2989.29亿4爱朋医疗-335.34254.764.0427.52亿5博晖 创新-330.17523.933.5248.44亿6硕世生物-127.7 ...

Core Insights - Xianheng International's stock closed at 14.67 yuan, up 1.17%, with a rolling PE ratio of 25.54, marking a new low in 33 days, and a total market capitalization of 6.02 billion yuan [1] - The average PE ratio in the instrument and meter industry is 81.17, with a median of 51.72, placing Xianheng International at the 28th position in the industry ranking [1] - As of March 31, 2025, the number of shareholders for Xianheng International increased to 14,219, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Company Overview - Xianheng International Technology Co., Ltd. specializes in the MRO (Maintenance, Repair, and Operations) of tools and instruments, engaging in the research, production, sales, and related technical services of these products [1] - The main products of the company include tools, instruments, and services [1] Financial Performance - In the latest quarterly report for Q1 2025, the company achieved a revenue of 640 million yuan, representing a year-on-year increase of 46.04%, and a net profit of 21.57 million yuan, up 144.43%, with a gross profit margin of 21.46% [1]

Group 1 - The core viewpoint of the article highlights that 科锐国际 (Core International) is experiencing a decline in stock price and has a relatively low PE ratio compared to its industry peers [1] - As of May 7, the stock price of 科锐国际 closed at 32.1 yuan, down 3.81%, with a rolling PE ratio of 28.40 times and a total market capitalization of 6.317 billion yuan [1] - The average PE ratio for the professional services industry is 56.67 times, with a median of 36.27 times, placing 科锐国际 at the 18th position in the industry ranking [1] Group 2 - In terms of capital flow, on May 7, there was a net outflow of 18.8873 million yuan from 科锐国际, with a total outflow of 11.9428 million yuan over the past five days [1] - The latest quarterly report for Q1 2025 shows that 科锐国际 achieved an operating revenue of 3.303 billion yuan, a year-on-year increase of 25.13%, and a net profit of 57.7839 million yuan, up 42.15% year-on-year, with a gross profit margin of 5.52% [1]

Group 1 - The core viewpoint of the article highlights Chengdu Xian Dao's current stock performance, with a closing price of 15.82 yuan, an increase of 1.54%, and a rolling PE ratio of 96.48, marking a new low in 20 days, with a total market value of 6.339 billion yuan [1] - Chengdu Xian Dao ranks 40th in the medical services industry based on PE ratio, which has an average of 38.66 and a median of 38.36 [1] - As of March 31, 2025, the number of shareholders for Chengdu Xian Dao has increased to 16,254, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - The main business of Chengdu Xian Dao includes drug early discovery and development services related to DEL technology, offering services such as DEL screening, DEL library customization, FBDD/SBDD, custom drug development, compound structure intellectual property transfer, and chemical synthesis [1] - In the latest quarterly report for Q1 2025, the company achieved an operating income of 107 million yuan, a year-on-year decrease of 0.60%, while net profit reached 28.2844 million yuan, a year-on-year increase of 102.90%, with a gross profit margin of 51.87% [1]

最新一期业绩显示，2025年一季报，公司实现营业收入1.82亿元，同比-72.47%；净利润1567.87万元， 同比-87.13%，销售毛利率42.78%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)105迪瑞医疗101.0025.481.7536.16亿行业平均 48.9047.004.53103.78亿行业中值36.4137.242.4046.92亿1天益医疗-1685.63-2887.291.8021.48亿2澳华内 镜-613.48307.694.9164.65亿3诺唯赞-417.99-494.372.2989.45亿4博晖创新-329.61523.043.5248.36亿5爱朋 医疗-325.82247.533.9226.73亿6硕世生物-125.93-1840.221.1336.84亿7奥精医疗-117.01-171.501.5421.72亿 8睿昂基因-98.61-80.961.4012.76亿9康泰医学-84.98-71.803.0355.93亿10中红医疗-67.51-53.850.8546.92亿 11华大智造-63.30-56.174.36337.46亿 从行业市盈率排名来 ...

Group 1 - The core viewpoint of the article highlights that Baoli International's stock price closed at 3.87 yuan, with a PE ratio of 168.81 times, significantly higher than the industry average of 45.59 times [1] - As of March 31, 2025, Baoli International had 40,212 shareholders, a decrease of 4,975 from the previous count, with an average holding value of 352,800 yuan per shareholder [1] - The main business of Baoli International includes the production and sales of various asphalt products, as well as helicopter and aviation material sales, and investment in BT projects [1] Group 2 - In the latest quarterly report for Q1 2025, Baoli International reported an operating revenue of 230 million yuan, a year-on-year decrease of 42.82%, and a net profit of 3.239 million yuan, down 26.61% year-on-year, with a gross profit margin of 1.83% [1] - The company ranks 154th in terms of PE ratio within the chemical products industry, which has an average PE of 45.59 times and a median of 38.06 times [2] - The total market capitalization of Baoli International is 3.567 billion yuan [1]

Group 1 - The core viewpoint of the articles highlights that Lepu Medical's stock closed at 11.41 yuan, with a PE ratio of 149.42, marking a new low in 20 days, and a total market capitalization of 21.458 billion yuan [1] - The average PE ratio for the medical device industry is 48.90, with a median of 36.41, positioning Lepu Medical at the 111th rank within the industry [1] - As of March 31, 2025, Lepu Medical has 94,228 shareholders, an increase of 583 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Group 2 - Lepu Medical's main business includes medical devices, pharmaceuticals, medical services, and health management, with its primary products being in these categories [1] - The latest quarterly report for Q1 2025 shows that the company achieved a revenue of 1.736 billion yuan, a year-on-year decrease of 9.67%, and a net profit of 379 million yuan, down 21.44%, with a gross profit margin of 64.03% [1] - The PE ratios for Lepu Medical are significantly higher than the industry averages, indicating potential overvaluation compared to peers [2]

Core Viewpoint - The company Feima International has a high rolling P/E ratio of 313.71, significantly above the industry average of 48.39, indicating potential overvaluation in the market [1][2]. Company Overview - Feima International specializes in supply chain management services and environmental new energy, with key products including comprehensive logistics services, trade execution services, and PPP project construction services [1]. - The company has established strong competitive advantages in business platform and operations, enterprise qualifications, management team, and brand reputation over years of exploration and accumulation [1]. Financial Performance - For Q1 2025, Feima International reported revenue of 54.66 million, a year-on-year decrease of 12.13%, and a net loss of approximately 768,248, indicating a significant decline of 112.24% compared to the previous year [1]. - The gross profit margin for the company stands at 29.66% [1]. Market Position - As of Q1 2025, Feima International ranks 116th in terms of P/E ratio within the environmental industry, which has an average P/E of 48.39 and a median of 29.42 [1][2]. - The total market capitalization of Feima International is approximately 6.733 billion [1][2]. Shareholding Structure - Eight institutions hold shares in Feima International, with a total of 1,006.18 million shares valued at 2.405 billion [1].

Group 1 - The core viewpoint of the articles highlights the performance and valuation of the company, Ribang Instrument, within the medical device industry, noting its recent stock price increase and market capitalization [1][2] - As of April 30, Ribang Instrument's closing price was 11.68 yuan, reflecting a 2.01% increase, with a rolling PE ratio of 35.88, marking a new low in 19 days, and a total market value of 6.77 billion yuan [1] - The average PE ratio for the medical device industry is 48.11, with a median of 35.88, positioning Ribang Instrument at the 75th rank within the industry [1][2] Group 2 - For the first quarter of 2025, Ribang Instrument reported an operating income of 420 million yuan, representing a year-on-year decrease of 5.25%, while net profit reached 65.09 million yuan, showing a significant increase of 68.98% [2] - The company's gross profit margin stands at 58.34%, indicating a strong profitability despite the decline in revenue [2] - As of the first quarter of 2025, two institutions held shares in Ribang Instrument, with a total holding of 48.78 million shares valued at 591 million yuan [1]

Group 1 - The core viewpoint of the articles highlights that Taishan Petroleum's stock closed at 5.98 yuan, down 1.64%, with a rolling PE ratio of 21.50 times and a total market value of 2.875 billion yuan [1] - The average PE ratio for the oil industry is 12.60 times, with a median of 25.37 times, placing Taishan Petroleum at the 14th position in the industry ranking [1] - As of April 18, 2025, the number of shareholders for Taishan Petroleum increased to 35,537, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Taishan Petroleum's main business includes wholesale and retail of refined oil products and non-oil products, with primary products being gasoline, diesel, natural gas, and non-oil items [1] - In the latest quarterly report for Q1 2025, the company reported an operating income of 802 million yuan, a year-on-year decrease of 4.76%, and a net profit of 52.9657 million yuan, a year-on-year increase of 185.74%, with a sales gross margin of 17.68% [1] - The PE (TTM) ratio for Taishan Petroleum is 21.50, while the static PE is 28.95, and the price-to-book ratio is 2.63 [2]